Co-Diagnostics

Co-Diagnostics, Inc. engages in the development and innovation of molecular tools for detection of infectious diseases, liquid biopsy for cancer screening, and agricultural applications. Its diagnostics systems enable very rapid, low-cost, molecular testing for organisms and genetic diseases by automating historically complex procedures in both the development and administration of tests. The company was founded by Brent C. Satterfield and Dwight Howard Egan on April 18, 2013 and is headquartered in Salt Lake City, UT.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Co-Diagnostics reports Q1 results, focuses on growth and innovation

Co-Diagnostics reported mixed financial results for Q1 2024, with revenue decrease but gross profit increase.
The company is strategically focused on commercialization efforts, product development, and managing expenses for growth.
Despite facing challenges such as net losses and operational complexities, Co-Diagnostics remains optimistic about future opportunities.
With a strong cash position and ongoing FDA submissions, Co-Diagnostics is poised for potential revenue growth and market expansion.

Co-Diagnostics reports Q3 revenue decline, focuses on global expansion

Co-Diagnostics faces financial challenges with a significant net loss in Q3 2024 but maintains a strong focus on advancing its testing platforms and expanding manufacturing capabilities.
Strategic opportunities in international market expansion and test development supported by grants present avenues for growth and market penetration.
Efforts to manage cash position through efficient spending and operational efficiencies underscore the company's commitment to future commercial success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Co-Diagnostics (NASDAQ:CODX) Inc announced that it has completed the acquisition of Idaho Molecular Inc and Advanced Conception Inc to provide the company with all existing and future assets and intellectual property related to its upcoming at-home/point-of-care diagnostic device. The transaction was settled for 4.72 million shares of Co-Diagnostics (NASDAQ:CODX) stock, and additional common warrants totaling 465,000.

Co-Diagnostics completes acquisition of Idaho Molecular and Advanced Conception to expand its at-home/point-of-care diagnostic device

SALT LAKE CITY, Dec. 31, 2021 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that it has completed the acquisition of Idaho Molecular Inc. and Advanced Conceptions, Inc. for nearly 4.72 million shares of the Company's stock, plus additional common warrants totaling 465,000, providing Co-Diagnostics with all existing and future assets and intellectual property related to the Company's upcoming at-home/point-of-care diagnostic device. The acquisition, first announced on December 22 , is expected to streamline the commercialization of the Eikon™ platform and YourTest™ PCR device as it nears completion.

Co-Diagnostics, Inc. Announces Completion of the Acquisition of all Assets and Intellectual Property Related to At-Home/Point-of-Care Platform

Ocugen, Inc.

Sorrento Therapeutics Inc

Even with COVID-19 cases rising, the prospects for these stocks remain uncertain.

Why Co-Diagnostics, Ocugen, and Sorrento Stocks Are Sinking This Week

The molecular testing company is expected to benefit from the rise in cases of the omicron COVID-19 variant.

Why Co-Diagnostics Stock Rose 15.8% on Monday

Develops products to detect infectious diseases in humans and animals Offers Logix Smart coronavirus detection test in US and globally Amassed balance sheet of $72.4 million What Co-Diagnostics does:  Co-Diagnostics Inc is a molecular diagnostics company that develops products to detect infectious diseases in humans and animals. The company also develops tools for liquid-biopsy cancer screening and agricultural uses.

Co-Diagnostics fighting coronavirus (COVID-19) with flagship test, plans at-home PCR-based platform

Co-Diagnostics (NASDAQ:CODX) Inc announced that it has signed agreements to acquire Idaho Molecular Inc and Advance Conceptions Inc for the development of its upcoming at-home/point-of-care diagnostic device. The Utah-based company said that the transactions will provide it with all the existing and future assets and intellectual property related to the upcoming platform.

Co-Diagnostics signs agreement to acquire Idaho Molecular and Advanced Conception for its at-home/point-of-care platform

SALT LAKE CITY, Dec. 22, 2021 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that it has entered into definitive agreements with each of Idaho Molecular Inc. and Advanced Conceptions, Inc., pursuant to which each of them will become wholly owned subsidiaries of Co-Dx. Co-Dx has been working with Idaho Molecular and Advanced Conceptions on the development of Co-Diagnostics' upcoming at-home/point-of-care diagnostic device.

Co-Diagnostics, Inc. Signs Agreement to Acquire all Assets and Intellectual Property Related to At-Home/Point-of-Care Platform

CVS Health

Kelly Services

Lowe's

NextEra Energy

QuidelOrtho Corp

Winnebago

With the omicron variant presenting uncertainties regarding how governments will react, here are some stocks to buy to counter that risk. The post 7 Stocks to Buy to Hedge Against Omicron Variant Risks appeared first on InvestorPlace.

7 Stocks to Buy to Hedge Against Omicron Variant Risks

Co-Diagnostics (NASDAQ:CODX) Inc said it has partnered with TiiCKER—a consumer shareholder loyalty platform—to increase its connection to retail investors.  The Salt Lake City-based company has teamed up with TiiCKER to reach new and existing investors, verify its shareholders and stock perks, and connect with retail investors interested in learning more about its world-class testing services and technology.

Co-Diagnostics partners with TiiCKER to increase connection with retail investors

SALT LAKE CITY, Dec. 7, 2021 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX), a molecular diagnostics company that develops and manufactures state-of-the-art diagnostics technology used in over 50 countries, announced a partnership with TiiCKER™; a consumer shareholder loyalty platform, to increase its connection to retail investors. Co-Diagnostics is teaming with TiiCKER to reach new and existing investors, verify its shareholders and stock perks, and connect with retail investors interested in learning more about their world-class testing services and technology via www.TiiCKER.com/CODX.

Creator of COVID-19 and Global Molecular Testing Products Co-Diagnostics, Inc. Launches Retail Investor and Perks Program with TiiCKER

Co-Diagnostics (NASDAQ:CODX) Inc, has announced that CoSara Diagnostics Pvt Ltd, its joint venture for manufacturing and sales in India, has received clearance from the Central Drugs Standard Control Organization (CDSCO) in India to manufacture and sell its SARAPLEX Flu A/Flu B/coronavirus (COVID-19) (ABC) RTPCR test as an in vitro diagnostic (IVD). The Salt Lake City, Utah-based molecular diagnostics company noted that CoSara's new test, the fourth CoSara assay to receive CDSCO approval this year and 11th overall, is built on the company's patented CoPrimer technology and designed for the simultaneous detection and differentiation of influenza A, influenza B, and SARS-CoV-2 (ABC).

Co-diagnostics JV CoSara receives clearance from Indian regulators for ABC Multiplex Test.

SALT LAKE CITY, Dec. 7, 2021 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that CoSara Diagnostics Pvt Ltd ("CoSara," or the "JV"), its joint venture for manufacturing and sales in India, has received clearance by the Central Drugs Standard Control Organization ("CDSCO") in India to manufacture and sell its SARAPLEX™ Flu A/Flu B/COVID-19 (ABC) RT-PCR test as an in vitro diagnostic ("IVD"). CoSara's new test, the 4th CoSara assay to receive CDSCO approval this year and 11th overall, is built on the Company's patented CoPrimer™ technology and designed for the simultaneous detection and differentiation of influenza A, influenza B, and SARS-CoV-2.

Co-Diagnostics JV CoSara Receives Clearance from Indian Regulators for ABC Multiplex Test

Co-Diagnostics Inc. (NASDAQ:CODX) shares gapped higher Monday, but have since fallen and are now trading lower. The company said today its COVID-19 diagnostics are not affected by the omicron variant.

Co-Diagnostics Stock Sees Movement After Company Says Products Unaffected By Omicron Variant

Co-Diagnostics (NASDAQ:CODX) Inc., which has a patented platform for the development of molecular diagnostic tests, revealed that none of the mutations in the heavily mutated SARS-CoV-2 variant recently discovered in Africa are expected to interfere with any of its suite of coronavirus (COVID-19) PCR diagnostic assays. The Salt Lake City, Utah-based molecular diagnostics company said that the new coronavirus strain includes more than 50 mutations, over 30 of which are found on the virus's spike protein, the main target of the body's immune responses, and is currently being studied to determine whether the mutations lead to increased transmissibility, or ability to evade the body's immune response.

Co-Diagnostics says its suite of coronavirus diagnostics not affected by heavily mutated Omicron variant

SALT LAKE CITY, Nov. 29, 2021 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, reported today that none of the mutations in the heavily mutated SARS-CoV-2 variant recently discovered in Africa are predicted to interfere with any of the Company's suite of COVID-19 PCR diagnostic assays. None of the mutations in the Omicron variant interfere with any of the Company's COVID-19 PCR diagnostic assays The new coronavirus strain includes more than 50 mutations, over 30 of which are found on the virus's spike protein, the main target of the body's immune responses, and is currently being studied to determine whether the mutations lead to increased transmissibility or ability to evade the body's immune response.

Co-Diagnostics, Inc. Reports that Suite of COVID-19 Diagnostics Not Affected by Heavily Mutated Omicron Variant

SALT LAKE CITY, Nov. 15, 2021 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq-CM: CODX) (the "Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that it will be hosting a booth this week at the MEDICA 2021 trade fair in Düsseldorf, Germany from 15-18 November. The Fair is expected to include around 2,900 exhibitors from 70 countries, returning to an in-person trade show for the first time following the onset of the pandemic.

Co-Diagnostics, Inc. to Host Booth at MEDICA 2021 Trade Fair in Düsseldorf, Germany

The company absolutely crushed analysts' Q3 estimates.

Why Co-Diagnostics Shot Almost 8% Higher Today

The stock price of Co-Diagnostics Inc (NASDAQ: CODX) increased by over 6% pre-market today. This is why it happened.

Co-Diagnostics (CODX) Stock: Why The Price Increased Today

Co-Diagnostics, Inc. (CODX) CEO Dwight Egan on Q3 2021 Results - Earnings Call Transcript

Co-Diagnostics (NASDAQ:CODX) Inc has announced record third-quarter 2021 revenue of $30.1 million, a 38% year-over-year increase, which the company attributed primarily to sales of its Logix Smart coronavirus (COVID-19) test. Co-Diagnostics (NASDAQ:CODX) also recorded a 67.5% increase in its gross profit for the quarter to $26.8 million, representing 89% of consolidated revenue due to improved product mix as compared to the same period last year.

Co-Diagnostics sees record 3Q revenue of $30.1M on Logix Smart coronavirus test sales

SALT LAKE CITY, Nov. 11, 2021 /PRNewswire/ -- Co-Diagnostics, Inc. (NASDAQ: CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today financial results for the third quarter ended September 30, 2021. Solid quarterly results highlighted by record revenue of $30.1 million, and fully diluted EPS of $0.38     Third Quarter 2021 Financial Results: Revenue increased 38.0% as compared to the prior year period to a record $30.1 million, primarily due to sales of the Logix Smart™ COVID-19 Test.

Co-Diagnostics Reports Continued Strength in Third Quarter 2021 Financial Results

Co-Diagnostics (NASDAQ:CODX) Inc has said it will be awarded the 'Innovation Impact Award' at the 2021 BioUtah Life Sciences awards which will be presented on Friday, November 12, 2021, during a virtual ceremony in which pre-recorded videos of the winners will be unveiled.  Co-Diagnostics CEO Dwight Egan will accept the award on behalf of the company.

Co-Diagnostics says it will be awarded the 'Innovation Impact Award' at the 2021 BioUtah Life Sciences awards

CoDiagnostics, Inc. (CODX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Analysts Estimate CoDiagnostics, Inc. (CODX) to Report a Decline in Earnings: What to Look Out for

Co-Diagnostics (NASDAQ:CODX) Inc has announced that its Logix Smart SARS-CoV-2 2-Gene multiplex test is now available for sale in the UK after being validated according to the United Kingdom Health Security Agency's (UKHSA) Medical Devices Regulations 2021 under Coronavirus Test Device Approvals (CTDA). The company said the Logix Smart test is available for sale through Client Life Science, Co-Diagnostics (NASDAQ:CODX)' authorized distributor in the UK.

Co-Diagnostics says its Logix Smart COVID-19 test has been approved for sale in the UK

SALT LAKE CITY, Nov. 4, 2021 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX), a molecular diagnostics company with a unique, patented platform for the development of diagnostic tests, announced today that its Logix Smart™ SARS-CoV-2 2-Gene multiplex test has been validated according to the United Kingdom Health Security Agency's ("UKHSA") Medical Devices (Coronavirus Test Device Approvals) (Amendment) Regulations 2021 ("CTDA") and is available for sale in the UK under the Regulation. The UKHSA is the agency responsible for planning, preventing, and responding to external health threats, replacing Public Health England earlier this year.

News for Co-Diagnostics Stock (CODX)